Microbial biofilm model, construction method thereof and application of microbial biofilm model in in-vitro simulation of chronic wounds

By constructing a microbial biofilm model, using animal source raw materials and collagen to simulate subcutaneous fat and dermis, and embed microorganisms through agar to form biofilm, the problem of ineffective simulation of chronic wounds in the existing technology is solved, and high in vitro Microbial biofilm simulation and maturity assessment of authenticity.

CN119020184APending Publication Date: 2024-11-26SUZHOU MICROPORT REGENERATIVE MEDICINE TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310582561.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-23
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The prior art has failed to effectively simulate the model of real human chronic wounds, and lacks a reliable method for building microbial biofilm model, making it difficult to simulate the behavior of microorganisms in chronic wounds in vitro.

Method used

A microbial biofilm model is provided, including a first structural layer, a second structural layer and a biofilm layer stacked in sequence. The first structural layer is composed of animal source raw materials and agar, and the second structural layer is a collagen hydrogel, and the biological The membrane layer contains specific types of microorganisms, and forms a biofilm model through agar-embedded microorganisms, and simulates tissue exudate using specific culture medium and buffer.

Benefits of technology

A microbial biofilm that simulates chronic wounds in vitro is realized, providing a microbial biofilm model with high authenticity and good reproducibility, which can simulate the environment of a real human chronic wound, and evaluate the maturity of biofilm through antibiotic resistance tests. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020184A_ABST
    Figure CN119020184A_ABST
Patent Text Reader

Abstract

The invention relates to a microbial biofilm model, a construction method thereof and application of the microbial biofilm model in in-vitro simulation of chronic wounds. The microbial biological membrane model comprises a first structural layer, a second structural layer and a biological membrane layer which are sequentially stacked and respectively correspond to a subcutaneous fat simulation layer, a dermis simulation layer and an in-vitro biological membrane, and the model has components similar to those of a chronic wound. The invention also provides a construction method of the microbial biofilm model, and the construction method can comprise a method for counting microorganisms in the microbial film layer. The invention further discloses an evaluation method for the maturity of the biological membrane layer. The components of the model culture medium are easy to obtain, the preparation mode and culture conditions are simple, and reproducibility and stability are good.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of biofilm models, and in particular to a microbial biofilm model and a construction method thereof, and an application thereof in simulating chronic wounds in vitro. Background Art

[0002] Bacterial biofilm is a key factor in chronic wound infection and difficulty in healing. There are a large number of microorganisms in nature. Once the microorganisms are adsorbed on the wound surface, they will multiply rapidly and produce extracellular polymers (EPS) such as polysaccharides, proteins and nucleic acids. These substances form a three-dimensional structure with microorganisms and water. Regarding the definition of biofilm, Malone et al. defined it as a bacterial aggregate that is tolerant to treatment and host defense, involving host wounds, microorganisms, EPS and the natural environment, and they maintain a complex and dynamic interaction. Biofilm is a miniature ecosystem that protects microorganisms from damage by the host immune system and drugs such as topical antibiotics. Therefore, the existence of biofilm makes the treatment of chronic wounds difficult. Therefore, the study of in vitro models of bacterial biofilms is extremely valuable.

[0003] There are many methods for preparing in vitro biofilms, including static biofilm models and dynamic biofilm models. Some in vitro biofilms are used to evaluate the antibacterial effects of antibiotics or antimicrobial agents, but no models that simulate real human chronic wounds have been found. In addition, there is currently no reliable method for constructing microbial biofilm models. Summary of the invention

[0004] Based on this, it is necessary to provide a microbial biofilm model and its construction method and its application in simulating chronic wounds in vitro.

[0005] In a first aspect of the present invention, a microbial biofilm model is provided, which comprises a first structural layer, a second structural layer and a biofilm layer stacked in sequence;

[0006] Wherein, the first structural layer comprises animal-derived raw materials and agar; the animal-derived raw materials comprise the following components: 5% to 15% (w / v) of animal subcutaneous fat, 2% to 6% (v / v) of sterile animal blood, 10% to 25% (v / v) of sterile animal serum and 55% to 80% (v / v) of a first microbial culture medium; in the first structural layer, the weight volume percentage of agar relative to the animal-derived raw materials is 0.3% to 0.8% (w / v);

[0007] The second structural layer is a hydrogel containing 1 mg / mL to 2 mg / mL type I collagen;

[0008] The biofilm layer comprises 103 ~10 5 The invention discloses a microorganism containing CFU and a second microorganism culture medium containing 0.3% to 0.8% (w / v) agar, wherein the microorganism comprises one of Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis and methicillin-resistant Staphylococcus aureus.

[0009] In some embodiments, the microbial biofilm model satisfies one or more of the following characteristics:

[0010] The animal-derived raw material is selected from one or more of pigs, cattle, sheep, horses, rabbits and mice;

[0011] The sterile animal blood is sterile defibrinated animal blood;

[0012] The first microbial culture medium is selected from any one of TSB and LB;

[0013] The matrix component in the second structural layer is cross-linked type I collagen;

[0014] The thickness of the first structural layer is 3 mm to 4 mm;

[0015] The thickness of the second structural layer is 0.4 mm to 0.8 mm;

[0016] The second microbial culture medium is any one of TSB and LB.

[0017] In some embodiments, the microbial biofilm model satisfies one or more of the following characteristics:

[0018] Feature a1: The animal-derived raw material comprises the following components: 5% to 15% (w / v) of animal subcutaneous fat, 2% to 6% (v / v) of sterile defibrinated animal blood, 15% to 25% (v / v) of sterile animal serum and 55% to 80% (v / v) of the first microbial culture medium; and

[0019] Feature b1: In the first structural layer, the weight volume percentage of agar relative to the animal-derived raw material is 0.3% to 0.5% (w / v).

[0020] In a second aspect of the present invention, a method for constructing a microbial biofilm model is provided, comprising the following steps:

[0021] The animal-derived raw material and agar are mixed to obtain a mixture A, which is solidified to form a first structural layer; wherein the animal-derived raw material comprises the following components: 5% to 15% (w / v) of animal subcutaneous fat, 2% to 6% (v / v) of sterile animal blood, 10% to 25% (v / v) of sterile animal serum and 55% to 80% (v / v) of a first microbial culture medium; in the first structural layer, the weight volume percentage of agar relative to the animal-derived raw material is 0.3% to 0.8% (w / v);

[0022] Covering at least a portion of the surface of the first structural layer with an aqueous solution C containing type I collagen, and forming a second structural layer through cross-linking; wherein the concentration of type I collagen in the aqueous solution C is 1 mg / mL to 2 mg / mL;

[0023] A mixed solution M containing microorganisms, a second microorganism culture medium and agar is inoculated onto at least a portion of the surface of the second structural layer and cultured until a biofilm layer is formed. The biofilm layer comprises 10 3 ~10 5 CFU of microorganisms; wherein the microorganism includes one of Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis and methicillin-resistant Staphylococcus.

[0024] In some embodiments, the maturity of the biofilm layer is determined using a maturity evaluation method comprising the following steps:

[0025] Providing a microbial film layer to be tested and a microbial bacterial suspension; wherein the number of microorganisms in the microbial bacterial suspension is similar to the number of microorganisms in the microbial film layer to be tested;

[0026] Provide antibiotic solution and sterile water, and simultaneously conduct the following four groups of experiments: Group 1: incubate the biofilm layer to be tested with the antibiotic solution; Group 2: incubate the biofilm layer to be tested with the sterile water; Group 3: incubate the microbial suspension with the antibiotic solution; Group 4: incubate the microbial suspension with the sterile aqueous solution; wherein the four experimental groups are incubated for the same time under the same environment; the antibiotics include at least one of gentamicin, vancomycin and tobramycin;

[0027] After the incubation, the number of microorganisms in the first, second, third and fourth groups of samples was tested and recorded as N z 、N p1 and N a and N p2 , calculate the parameter lg(N p1 )-lg(N z ) and the parameter lg (N p2)-lg(N a );

[0028] According to lg(N p2 )-lg(N a ) minus lg(N p1 )-lg(N z ) is used to obtain the resistance parameter Δlg of the microbial film layer to be tested. When Δlg≥1, it is determined that the microbial film layer to be tested is initially formed.

[0029] In some embodiments, the number of microorganisms in the microbial film layer to be detected is obtained by a method comprising the following steps:

[0030] In the presence of glass beads, the microbial film layer to be tested is vortexed and ultrasonically treated, and the number of microorganisms is measured by plate counting method after sampling from the suspension, and the number of microorganisms in the microbial film layer to be tested is calculated according to the measurement result of the plate counting method.

[0031] In some embodiments, the step of culturing until a biofilm layer is formed satisfies one or more of the following characteristics:

[0032] The culture temperature was 37°C;

[0033] The culture time is 25 to 168 hours;

[0034] Buffer B is replenished at least once every 24 hours; wherein the buffer B is a pH 7.0 sodium chloride peptone buffer; and the height of the buffer B replenished each time is 350 μm to 450 μm.

[0035] In some embodiments, the construction method satisfies one or more of the following characteristics:

[0036] The animal-derived raw material is selected from one of pigs, cattle, sheep, horses, rabbits and mice;

[0037] The first microbial culture medium is selected from any one of TSB and LB;

[0038] The second microbial culture medium is any one of TSB and LB;

[0039] The laying thickness of the mixture A is 3 mm to 4 mm;

[0040] The thickness of the first structural layer is 3 mm to 4 mm;

[0041] The aqueous solution C contains type I collagen at a concentration of 1 mg / mL to 2 mg / mL;

[0042] The volume ratio of the aqueous solution C to the mixture A is 1:(5-10);

[0043] The thickness of the aqueous solution C on the surface of the first structural layer is 0.4 mm to 0.8 mm;

[0044] The volume of the mixed solution M per unit area of ​​the second structural layer is 1.5 μL / cm 2 ~3.2μL / cm 2 .

[0045] In some embodiments, the mixed solution M is prepared by a method comprising the following steps: mixing the microbial suspension D with the culture medium M0 at 40 to 50° C.;

[0046] Wherein, the microbial suspension D contains the microorganisms and a fourth microbial culture medium; and the culture medium M0 contains agar and a third microbial culture medium.

[0047] In some embodiments, the construction method satisfies one or more of the following characteristics:

[0048] In the mixed solution M, the concentration of agar is 0.3% to 1.0% (w / v);

[0049] In the mixed solution M, the concentration of the microorganism is 10 5 ~10 7 CFU / mL;

[0050] In the mixed solution M, the number of microorganisms is 10 3 ~10 5 CFU;

[0051] In the culture medium M0, the mass volume ratio of agar to the third microbial culture medium is 0.5% to 1.0% (w / v);

[0052] The volume ratio of the microbial suspension D to the culture medium M0 is 0.02 to 0.05;

[0053] The microbial suspension D is prepared by a method comprising the following steps: culturing the microorganism in the fourth microbial culture medium at 37±1° C. for 18 h to 24 h;

[0054] The fourth microbial culture medium is selected from any one of TSB and LB;

[0055] The microbial suspension D contained 0.5×10 9 ~5×10 9 CFU / mL of the microorganism;

[0056] The third microbial culture medium is selected from any one of TSB or LB.

[0057] In some embodiments, the construction method satisfies one or more of the following characteristics:

[0058] Feature a2: The animal-derived raw material comprises the following components: 5% to 15% (w / v) of animal subcutaneous fat, 2% to 6% (v / v) of sterile defibrinated animal blood, 15% to 25% (v / v) of sterile animal serum and 55% to 80% (v / v) of a second microbial culture medium;

[0059] Feature b2: In the first structural layer, the weight volume percentage of agar relative to the animal-derived raw material is 0.3% to 0.5% (w / v).

[0060] In a third aspect of the present invention, there is provided an application of a double-layer membrane in preparing a microbial biofilm model, wherein the double-layer membrane comprises a first structural layer and a second structural layer stacked in layers; the microbial biofilm model comprises one of Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis and methicillin-resistant Staphylococcus aureus;

[0061] Wherein, the first structural layer and the second structural layer are as defined in the first aspect of the present invention.

[0062] In a fourth aspect of the present invention, there is provided use of the microbial biofilm model described in the first aspect of the present invention or the microbial biofilm model obtained by the construction method described in the second aspect of the present invention in simulating chronic wounds in vitro.

[0063] The present invention provides a microbial biofilm model, which includes a first structural layer, a second structural layer and a biofilm layer stacked in sequence, which correspond to a subcutaneous fat simulation layer, a dermis simulation layer and an in vitro biofilm, respectively. The model has components similar to chronic wounds. The model selects some nutrients such as fetal bovine serum, subcutaneous fat, sterile horse blood and other components to simulate the tissue structure below the dermis layer, and also selects collagen to simulate the dermis layer. In addition, agar is used to embed microorganisms in the in vitro biofilm. The model provides a model that simulates real human chronic wounds.

[0064] The method for constructing a microbial biofilm model provided by the present invention is based on a double-layer membrane composed of a subcutaneous fat simulation layer and a dermis simulation layer, and microorganisms are inoculated on the dermis simulation layer in an agar-embedded manner to form an initial biofilm model scaffold, and then microorganisms are cultured to form a biofilm structure, so as to obtain the aforementioned microbial biofilm model. The components of the model culture medium are easy to obtain, the preparation method and culture conditions are simple, and the reproducibility and stability are good. In addition, during the culture process, the model can also be constructed by simulating tissue exudate with a sodium chloride peptone buffer while preventing the biofilm from drying.

[0065] The construction method may include a method for counting microorganisms in a microbial film layer. Since some microorganisms are embedded in agar and some microorganisms grow into the solid matrix, once the biofilm is formed, it is hydrophobic and not easy to destroy. In order to accurately count, agar, collagen and biofilm are first dispersed by glass beads under high speed conditions, and then the microorganisms are further released by ultrasound. This method can improve the counting results of microorganisms and can accurately count the true value of microorganisms on the biofilm.

[0066] The construction method may also include a method for evaluating the maturity of the biofilm layer. In the present invention, starting from the perspective of the biofilm's resistance to antibiotics, the test results of administering the same dose after a period of time are used to reflect the resistance of the biofilm, thereby determining whether the biofilm is mature. The mature biofilm model determined in this way can provide assistance for biofilm treatment methods in the subsequent experimental stage. BRIEF DESCRIPTION OF THE DRAWINGS

[0067] In order to more clearly illustrate the technical solutions in the embodiments of the present application and to more completely understand the present application and its beneficial effects, the following is a brief introduction to the drawings required for use in the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present application. For those skilled in the art, other drawings can be obtained based on these drawings without creative work. It should also be noted that the drawings are all drawn in a simplified form and are only used to conveniently and clearly assist in explaining the present invention. The various sizes of each component shown in the drawings are arbitrarily shown and may be accurate or may not be drawn according to the actual scale. For example, in order to make the illustration clearer, the size of the components is appropriately exaggerated in some places in the drawings. Unless otherwise specified, the components in the figure are not drawn to scale. The present invention does not limit each size of each component.

[0068] In the following description, the same reference numerals denote the same parts.

[0069] Figure 1 This is a schematic diagram of the structure of a microbial biofilm model in one embodiment of the present invention; the model comprises a subcutaneous fat simulation layer, a dermis simulation layer and a biofilm from bottom to top, and the outer frame is a container.

[0070] Explanation of the reference numerals: Explanation of the reference numerals: 110 is a first structure, 120 is a second structure, 130 is a biofilm layer, 100 is a microbial biofilm model, and 200 is a culture container. DETAILED DESCRIPTION

[0071] The present invention will be further described in detail below in conjunction with the accompanying drawings, embodiments and examples. It should be understood that these embodiments and examples are only used to illustrate the present invention and are not used to limit the scope of the present invention. The purpose of providing these embodiments and examples is to make the understanding of the disclosure of the present invention more thorough and comprehensive. It should also be understood that the present invention can be implemented in many different forms and is not limited to the embodiments and examples described herein. Those skilled in the art can make various changes or modifications without violating the connotation of the present invention, and the equivalent forms obtained also fall within the protection scope of the present invention. For example, the features described or described as part of an embodiment can be combined in another embodiment in a suitable manner to produce a new embodiment. In addition, in the description below, a large number of specific details are given in order to provide a more comprehensive understanding of the present invention. It should be understood that the present invention can be implemented without one or more of these details.

[0072] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used in the specification of the present invention herein are only for the purpose of describing implementation modes and embodiments and are not intended to limit the present invention.

[0073] the term

[0074] Unless otherwise specified or incompatible herewith, the terms and phrases used herein shall have the following meanings:

[0075] The term "and / or" used herein includes any one of two or more related listed items, and also includes any and all combinations of the related listed items, which include any combination of any two related listed items, any more related listed items, or all related listed items. For example, "A and / or B" includes three parallel solutions: A, B, and "a combination of A and B".

[0076] In the present invention, "plurality", "multiple", "multiple times", etc., unless otherwise specified, refer to a number greater than 2 or equal to 2. For example, "one or more" means one or greater than or equal to two.

[0077] In the present invention, unless otherwise specified, "one or more" means any one of the listed items or any combination of the listed items. Similarly, "one or more" and other expressions that mean "one or more" are also understood in the same way unless otherwise specified.

[0078] As used herein, "combination thereof", "any combination thereof", "any combination thereof" etc. include all suitable combinations of any two or more of the listed items.

[0079] Herein, the “suitable” mentioned in “suitable combination”, “suitable method”, “any suitable method”, etc., shall be based on the ability to implement the technical solution of the present invention, solve the technical problem of the present invention, and achieve the expected technical effect of the present invention.

[0080] Herein, "preferred", "better", "more preferred" and "suitable" are only used to describe implementation methods or examples with better effects, and it should be understood that they do not constitute a limitation on the scope of protection of the present invention. If multiple "preferred" items appear in a technical solution, unless otherwise specified and there is no contradiction or mutual restriction, each "preferred" item is independent.

[0081] In the present invention, "further", "further", "particularly", "for example", "such as", "example", "for example", etc. are used for descriptive purposes, indicating that the previous and subsequent different technical solutions are related in terms of the contents covered, but should not be understood as limiting the previous technical solution, nor can they be understood as limiting the scope of protection of the present invention. In the present invention, unless otherwise specified, A (such as B) means that B is a non-limiting example of A, and it can be understood that A is not limited to B.

[0082] In the present invention, "optionally", "optional", and "optional" mean optional, that is, any one of the two parallel schemes of "yes" or "no". If multiple "optional" appear in a technical scheme, unless otherwise specified and there is no contradiction or mutual restriction, each "optional" is independent of each other. In this application, descriptions such as "optionally contain", "optionally include", etc. mean "contain or not contain". "Optional component X" means that component X exists or does not exist, or means that component X is contained or not contained.

[0083] In the present invention, in the "first aspect", "second aspect", "third aspect", "fourth aspect", etc., the terms "first", "second", "third", "fourth", etc. are used only for descriptive purposes and cannot be understood as indicating or implying relative importance or quantity, nor can they be understood as implicitly indicating the importance or quantity of the indicated technical features. Moreover, "first", "second", "third", "fourth", etc. only serve the purpose of non-exhaustive enumeration and description, and it should be understood that they do not constitute a closed limitation on quantity.

[0084] As used herein, the terms "comprising", "including" and "comprising" are synonymous and are inclusive or open-ended and do not exclude additional, unrecited members, elements or method steps.

[0085] In the present invention, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.

[0086] In the present invention, when it comes to a numerical interval (i.e., a numerical range), unless otherwise specified, the distribution of the optional numerical values ​​in the numerical interval is considered to be continuous, and includes the two numerical endpoints (i.e., the minimum value and the maximum value) of the numerical interval, and each numerical value between the two numerical endpoints. Unless otherwise specified, when the numerical interval only refers to the integers in the numerical interval, including the two endpoint integers of the numerical range, and each integer between the two endpoints, is equivalent to directly listing each integer. When multiple numerical ranges are provided to describe features or characteristics, these numerical ranges can be merged. In other words, unless otherwise specified, the numerical ranges disclosed herein should be understood to include any and all sub-ranges included therein. The "numerical value" in the numerical interval can be any quantitative value, such as a number, a percentage, a ratio, etc. "Numerical interval" allows broadly including numerical interval types such as percentage intervals, ratio intervals, and ratio intervals.

[0087] The temperature parameters in the present invention, if not specifically limited, are allowed to be either constant temperature treatment or to vary within a certain temperature range. It should be understood that the constant temperature treatment allows the temperature to fluctuate within the precision range controlled by the instrument. Fluctuations within the range of ±5°C, ±4°C, ±3°C, ±2°C, and ±1°C are allowed.

[0088] In the present invention, the term "room temperature" or "normal temperature" generally refers to 4°C to 35°C, for example, 20°C ± 5°C. In some embodiments of the present invention, "room temperature" or "normal temperature" refers to 10°C to 30°C. In some embodiments of the present invention, "room temperature" or "normal temperature" refers to 20°C to 30°C.

[0089] In the present invention, when it comes to the unit of the data range, if there is a unit only after the right endpoint, it means that the units of the left endpoint and the right endpoint are the same. For example, 3-5h means that the units of the left endpoint "3" and the right endpoint "5" are both h (hours).

[0090] In this article, unless otherwise specified, "about" means within a certain range above or below the number, and the fluctuation range may vary depending on the type and value of the number. For example, it is allowed to be within a range of ±10%, ±5%, ±2%, ±1%, etc. For example, about 45°C can be selected from 45±1°C.

[0091] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as a reference separately. Unless they conflict with the invention purpose and / or technical solution of the present application, the cited documents involved in the present invention are cited with all contents and all purposes. When the present invention involves cited documents, the definitions of relevant technical features, terms, nouns, phrases, etc. in the cited documents are also cited. When the present invention involves cited documents, the examples and preferred embodiments of the cited relevant technical features may also be incorporated into this application as references, but are limited to the ability to implement the present invention. It should be understood that when the content of the citation conflicts with the description in this application, the present application shall prevail or be modified adaptively according to the description of this application.

[0092] In the present invention, if there are multiple steps involved in the method flow, unless otherwise specified herein, there is no strict order restriction on the execution of these steps, and they can be executed in other orders than described. Moreover, any step can include multiple sub-steps or multiple stages, and these sub-steps or stages are not necessarily executed at the same time, but can be executed at different times, and their execution order is not necessarily sequential, but can be executed in turn, alternating or simultaneously with other steps or parts of sub-steps or stages of other steps.

[0093] The mass or weight of the relevant components mentioned in the description of the embodiments of the present invention may not only refer to the specific content of each component, but also indicate the proportional relationship of the mass or weight between the components. Therefore, as long as the content of the relevant components is proportionally enlarged or reduced according to the description of the embodiments of the present invention, it is within the scope disclosed in the description of the embodiments of the present invention. Specifically, the mass or weight described in the description of the embodiments of the present invention may be units known in the chemical industry such as μg, mg, g, and kg.

[0094] Herein, unless otherwise specified, Sa is the abbreviation of Staphylococcus aureus; Pa is the abbreviation of Pseudomonas aeruginosa. TSB medium is a tryptic soy peptone liquid medium, and LB medium is a medium well known to those skilled in the art and can be purchased commercially.

[0095] At present, there is no model that simulates real human chronic wounds. This may be attributed to the complex influence of differences in culture time, culture temperature, and culture medium composition. Furthermore, there is currently no evaluation method as to whether the microbial biofilm model is mature and successfully constructed.

[0096] In a first aspect of the present invention, a microbial biofilm model 100 is provided, which comprises a first structural layer 110, a second structural layer 120 and a biofilm layer 130 stacked in sequence, corresponding to a subcutaneous fat simulation layer, a dermis simulation layer and an in vitro biofilm, respectively (see Figure 1), the model has components similar to chronic wounds. The model selects some nutrients such as fetal bovine serum, subcutaneous fat, sterile horse blood and other components to simulate the tissue structure below the dermis, and also selects collagen to simulate the dermis. In addition, agar is used to embed microorganisms in the in vitro biofilm. The model provides a model that simulates real human chronic wounds. The microbial biological model is prepared in a culture container 200. Unless otherwise specified, the culture container 200 is covered with a sterile cover (such as a sterile PE cover), but it can be exchanged with air, and can truly simulate human chronic wounds.

[0097] In some embodiments, a microbial biofilm model is provided, which includes a first structural layer, a second structural layer, and a biofilm layer stacked in sequence; wherein the first structural layer includes animal-derived raw materials and agar; the second structural layer is a hydrogel including collagen; and the biofilm layer includes microorganisms and agar. The wound structure of the skin is simulated by stacking the two structural layers, which can not only allow microorganisms to attach and grow thereon, providing a breeding ground, but also can simulate the main nutrient range on chronic wounds as realistically as possible.

[0098] In some embodiments, the microorganism includes one of Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis and methicillin-resistant Staphylococcus aureus, and can further be any one of Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis and methicillin-resistant Staphylococcus aureus.

[0099] In some embodiments, the animal-derived raw material comprises animal subcutaneous fat, sterile animal blood, sterile animal serum and a microbial culture medium (referred to as the first microbial culture medium in this application). The first microbial culture medium can be selected from any one of TSB and LB.

[0100] In some embodiments, the animal-derived raw material comprises the following components: 5% to 15% (w / v) animal subcutaneous fat, 2% to 6% (v / v) sterile animal blood, 10% to 25% (v / v) sterile animal serum and 55% to 80% (v / v) microbial culture medium.

[0101] In some embodiments, in the first structural layer, the weight percentage of agar relative to the animal-derived raw material is 0.3% to 0.8% (w / w).

[0102] In some embodiments, the second structural layer is a collagen-based hydrogel, and the matrix component is cross-linked collagen. The second structural layer can be formed by cross-linking an aqueous solution of collagen, and the aqueous solution can contain a pH regulator.

[0103] In the present invention, the "matrix component" of the hydrogel refers to the component constituting the three-dimensional network of the hydrogel.

[0104] Unless otherwise specified, the collagen in the second structural layer is type I collagen. It can further be rat tail type I collagen. It is understood that the type I collagen here is cross-linked type I collagen.

[0105] In some embodiments, the second structural layer is a hydrogel comprising type I collagen.

[0106] In some embodiments, the second structural layer may be a type I collagen-based hydrogel, in which case the matrix component in the second structural layer is type I collagen. It can be understood that the matrix component type I collagen here is cross-linked type I collagen.

[0107] In some embodiments, the biofilm layer comprises microorganisms, agar and a microorganism culture medium (which may be referred to as a second microorganism culture medium). The second microorganism culture medium may be selected from any one of TSB and LB, and may further be a TSB culture medium.

[0108] In some embodiments, the number of microorganisms in the biofilm layer is 10 3 ~10 5 CFU, which is 3 to 5 logarithmic values.

[0109] In this application, the number of microorganisms is expressed as "n logarithmic value": the number of microorganisms is 10 n CFU, where one logarithmic value represents 10 1 CFU, "3 to 5 logarithmic values ​​of microorganisms" means 10 3 ~10 5 CFU of microorganisms.

[0110] In some embodiments, in the biofilm layer, the concentration of agar in the second microbial culture medium is 0.3% to 0.8% (w / w).

[0111] In some embodiments, the biofilm layer comprises 10 3 ~10 5 CFU of microorganisms and a second microorganism culture medium containing 0.3% to 0.8% (w / v) agar. Further, the microorganism is as defined above, for example, can include one of Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis and methicillin-resistant Staphylococcus aureus.

[0112] In some embodiments, a microbial biofilm model is provided, comprising a first structural layer, a second structural layer, and a biofilm layer stacked in sequence;

[0113] Wherein, the first structural layer comprises animal-derived raw materials and agar; the animal-derived raw materials comprise the following components: 5% to 15% (w / v) of animal subcutaneous fat, 2% to 6% (v / v) of sterile animal blood, 10% to 25% (v / v) of animal serum and 55% to 80% (v / v) of microbial culture medium (herein, the first microbial culture medium); optionally, in the first structural layer, the weight volume percentage of agar relative to the animal-derived raw materials is 0.3% to 0.8% (w / v);

[0114] The second structural layer is a hydrogel containing 1 mg / mL to 2 mg / mL type I collagen;

[0115] The biofilm layer comprises microorganisms and a microorganism culture medium containing agar (herein, the second microorganism culture medium); optionally, the number of microorganisms in the biofilm layer is 10 3 ~10 5 CFU, the concentration of agar in the second microbial culture medium is 0.3% to 0.8%; further optionally, the microorganism includes one of Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis and methicillin-resistant Staphylococcus aureus.

[0116] In the present invention, "CFU" is a unit of measurement for the number of microorganisms and has a well-known meaning in the technical field.

[0117] In some embodiments, the thickness of the first structural layer is 3 mm to 4 mm, for example, 3.0 mm, 3.2 mm, 3.5 mm, 3.6 mm, 3.8 mm, 4.0 mm, etc.

[0118] In some embodiments, the source of the animal-derived raw material is selected from one of pigs, cattle, sheep, horses, rabbits, mice, etc.

[0119] In some embodiments, in the animal-derived raw material, the weight volume percentage of animal subcutaneous fat is 5% to 15% (w / v), for example 5%, 6%, 8%, 10%, 12%, 15%, etc., and can also be selected from the interval consisting of any two of the aforementioned percentages.

[0120] In some embodiments, in the animal-derived raw material, the volume percentage of sterile animal blood is 2% to 6% (v / v), for example 2%, 3%, 4%, 5%, 6%, etc., and can also be selected from the interval consisting of any two of the aforementioned percentages, such as 3% to 6%, 4% to 6%, etc.

[0121] In some embodiments, in the animal-derived raw material, the sterile animal blood may be defibrinated. In some non-limiting examples, the sterile animal blood is sterile defibrinated animal blood, such as sterile defibrinated horse blood.

[0122] In some embodiments, in the animal-derived raw material, the volume percentage of sterile animal serum is 10% to 25% (v / v), such as 10%, 15%, 20%, 25%, etc., and can also be selected from the interval consisting of any two of the aforementioned percentages.

[0123] In some embodiments, in the animal-derived raw material, the volume percentage of the first microbial culture medium is 55% to 80% (v / v), for example, 55%, 60%, 65%, 70%, 75%, 78%, 80%, etc., and can also be selected from the interval consisting of any two of the aforementioned percentages, for example, 55% to 78%, 55% to 70%, 60% to 80%, etc.

[0124] In some embodiments, in the first structural layer, the weight volume percentage of agar relative to the animal-derived raw material is 0.3% to 0.8% (w / v), for example, 0.3% (w / v), 0.4% (w / v), 0.5% (w / v), 0.6% (w / v), 0.7% (w / v), 0.8% (w / v), etc., and can also be selected from the interval consisting of any two of the aforementioned percentages. For example, 0.3% (w / v), 0.4% (w / v), 0.5% (w / v), 0.6% (w / v), 0.7% (w / v), 0.8% (w / v), etc., and can also be selected from the interval consisting of any two of the aforementioned percentages, such as 0.3% to 0.5% (w / v).

[0125] In some embodiments, the thickness of the second structural layer is 0.4 mm to 0.6 mm, for example, 0.40 mm, 0.45 mm, 0.50 mm, 0.55 mm, 0.60 mm, etc.

[0126] In some embodiments, the second structural layer is a hydrogel containing 1 mg / mL to 2 mg / mL of type I collagen. The content of type I collagen in the second structural layer can be 1 mg / mL, 1.5 mg / mL, 2 mg / mL, etc.

[0127] In some embodiments, in the biofilm layer, the concentration of agar in the second microbial culture medium is 0.3% to 0.8% (w / w), for example, 0.3% (w / v), 0.4% (w / v), 0.5% (w / v), 0.6% (w / v), 0.7% (w / v), 0.8% (w / v), etc., and can also be selected from the interval consisting of any two of the aforementioned percentages.

[0128] A culture container 200 with a suitable culture area can be selected according to the model size, and a flat-bottom culture plate can be selected. The specifications of the culture plate can be, for example, a 6-well plate, a 12-well plate, etc. Accordingly, the area of ​​the biofilm layer can be 9.6 cm 2 、4.5cm2 wait.

[0129] In some embodiments, the area of ​​the biofilm layer is 4.5 cm 2 ~9.6cm 2 .

[0130] In some embodiments, the thickness of the biofilm layer is 300 μm to 500 μm as observed under a fluorescence microscope. Unless otherwise specified, the "thickness of the biofilm layer" refers to the maximum value of the thickness values ​​at different locations.

[0131] In some embodiments, the microbial biofilm model satisfies one or more of the following characteristics:

[0132] The animal-derived raw materials are selected from one or more of pigs, cattle, sheep, horses, rabbits, mice, etc.;

[0133] The microbial culture medium is selected from any one of TSB and LB;

[0134] The second structural layer is a hydrogel of type I collagen;

[0135] The thickness of the first structural layer is 3 mm to 4 mm;

[0136] The thickness of the second structural layer is 0.4 mm to 0.8 mm;

[0137] The second microbial culture medium is selected from any one of TSB and LB.

[0138] In some embodiments, the animal-derived raw material comprises the following components: 5% to 15% (w / v) animal subcutaneous fat, 2% to 6% (v / v) (further such as 3% to 6% (v / v)) of sterile animal blood (such as sterile defibrinated animal blood), 10% to 25% (v / v) (further such as 10% to 20% (v / v), 15% to 25% (v / v), etc.) of sterile animal serum and 55% to 80% (v / v) (further such as 55% to 70% (v / v), 60% to 80% (v / v), etc.) of microbial culture medium.

[0139] In some embodiments, in the first structural layer, the weight volume percentage of agar relative to the animal-derived raw material is 0.3% to 0.5% (w / v).

[0140] In some embodiments, the animal-derived raw material comprises the following components: 5% to 15% (w / v) animal subcutaneous fat, 2% to 6% (v / v) (further such as 3% to 6% (v / v)) of sterile animal blood (such as sterile defibrinated animal blood), 10% to 25% (v / v) (further such as 10% to 20% (v / v), 15% to 25% (v / v), etc.) of sterile animal serum and 55% to 80% (v / v) (further such as 55% to 70% (v / v), 60% to 80% (v / v), etc.) of microbial culture medium; in the first structural layer, the weight volume percentage of agar relative to the animal-derived raw material is 0.3% to 0.8% (w / v) (further such as 0.3% to 0.5% (w / v)).

[0141] In the second aspect of the present invention, a method for constructing a microbial biofilm model is provided, which can be used to construct the microbial biofilm model of the first aspect of the present invention. A method for preparing an in vitro biofilm model is provided.

[0142] The method for constructing a microbial biofilm model provided by the present invention is based on a double-layer membrane composed of a subcutaneous fat simulation layer and a dermis simulation layer, and microorganisms are inoculated on the dermis simulation layer in an agar embedding manner to form an initial biofilm model scaffold, and then microorganisms are cultured to form a biofilm structure, so as to obtain the aforementioned microbial biofilm model. The components of the model culture medium are easy to obtain, the preparation method and culture conditions are simple, and the reproducibility and stability are good.

[0143] By analyzing the main components of skin structure and chronic wounds, solid culture medium is prepared by mixing various ingredients, and microorganisms are inoculated to form a mature biofilm structure. In addition, the number of biofilm microorganisms is determined by optimizing the counting method, and the maturity of the biofilm is determined by biofilm resistance analysis.

[0144] In the method for constructing an in vitro biofilm model provided by the present invention, the biofilm model constructed by the method is mainly divided into two layers, one is a subcutaneous fat simulation layer (denoted as the first structural layer) containing animal-derived raw materials and culture medium, and the other is a dermis simulation layer (denoted as the second structural layer) based on collagen hydrogel. The wound structure of the skin is simulated by superposition of the two structural layers, which can enable microorganisms to attach and grow thereon to provide a breeding ground, and can also simulate the main nutrient content range of chronic wounds as realistically as possible.

[0145] In some embodiments, a method for constructing a microbial biofilm model is provided, comprising the following steps:

[0146] S100: mixing the animal-derived raw material and agar to obtain a mixture A, which is solidified to form a first structural layer; further, the animal-derived raw material comprises animal subcutaneous fat, sterile animal blood, sterile animal serum and a first microbial culture medium;

[0147] S200: covering at least a portion of the surface of the first structural layer with a solution C containing collagen, and forming a second structural layer through cross-linking;

[0148] S300: inoculating a mixed solution M containing microorganisms, a second microorganism culture medium and agar onto at least a portion of the surface of the second structural layer, and culturing until a biofilm layer is formed.

[0149] The types and amounts of the various raw materials may refer to the first aspect of the present invention.

[0150] In the present invention, unless otherwise specified, the collagen in step S200 is type I collagen.

[0151] In the present invention, unless otherwise specified, "culturing until a biofilm layer is formed" can be culturing under air conditions. More specifically, the culture container is covered with a sterile cover (such as a sterile PE cover) but can be exchanged with air.

[0152] In step S300, the microorganism may include one of Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis and methicillin-resistant Staphylococcus aureus, and may further be any one of Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis and methicillin-resistant Staphylococcus aureus.

[0153] In some embodiments, a method for constructing a microbial biofilm model is provided, comprising the following steps:

[0154] S100: mixing an animal-derived raw material and agar to obtain a mixture A, which is solidified to form a first structural layer; wherein the animal-derived raw material comprises the following components: 5% to 15% (w / v) of animal subcutaneous fat, 2% to 6% (v / v) of sterile animal blood, 10% to 25% (v / v) of sterile animal serum, and 55% to 80% (v / v) of a first microbial culture medium; in the first structural layer, the weight volume percentage of agar relative to the animal-derived raw material is 0.3% to 0.8% (w / v);

[0155] S200: Covering at least a portion of the surface of the first structural layer with an aqueous solution C containing type I collagen, and forming a second structural layer through cross-linking; wherein the concentration of type I collagen in the aqueous solution C is 1 mg / mL to 2 mg / mL;

[0156] S300: Inoculate a mixed solution M containing microorganisms, a second microorganism culture medium and agar onto at least a portion of the surface of the second structural layer, and culture until a biofilm layer is formed. Optionally, the biofilm layer comprises 10 3 ~10 5 CFU of microorganisms.

[0157] In some embodiments, the source of the animal-derived raw material is selected from one or more of pigs, cattle, sheep, horses, rabbits, mice, etc.

[0158] The composition of the animal-derived raw material can refer to the first aspect of the present invention, and the types and concentrations of the components of the animal-derived raw material can be defined as in the first aspect of the present invention. For example, in some embodiments, the animal-derived raw material comprises the following components: 5% to 15% (w / v) of animal subcutaneous fat, 2% to 6% (v / v) of sterile animal blood (such as sterile defibrinated animal blood), 10% to 25% (v / v) of sterile animal serum, and 55% to 80% (v / v) of microbial culture medium.

[0159] In some embodiments, in the first structural layer, the weight volume percentage of agar relative to the animal-derived raw material is 0.3% to 0.8% (w / v). Reference may also be made to the first aspect of the present invention. For example, 0.3% (w / v), 0.4% (w / v), 0.5% (w / v), 0.6% (w / v), 0.7% (w / v), 0.8% (w / v), etc., and may also be selected from the interval consisting of any two of the aforementioned percentages.

[0160] In some embodiments, the animal-derived raw material comprises the following components: 5% to 15% (w / v) animal subcutaneous fat, 2% to 6% (v / v) (further such as 3% to 6% (v / v)) sterile animal blood (such as sterile defibrinated animal blood), 10% to 25% (v / v) (further such as 10% to 20% (v / v), 15% to 25% (v / v), etc.) animal serum and 55% to 80% (v / v) (further such as 55% to 70% (v / v), 60% to 80% (v / v), etc.) microbial culture medium; in the first structural layer, the weight volume percentage of agar relative to the animal-derived raw material is 0.3% to 0.8% (w / v) (further such as 0.3% to 0.5% (w / v)).

[0161] In some embodiments, the first microbial culture medium is selected from any one of TSB and LB.

[0162] In some embodiments, the first microbial culture medium is TSB medium.

[0163] In some embodiments, the laying thickness of the mixture A is 3 mm to 4 mm, for example, 3.0 mm, 3.2 mm, 3.5 mm, 3.6 mm, 3.8 mm, 4.0 mm, etc.

[0164] In some embodiments, the thickness of the first structural layer can refer to the definition of the first aspect of the present invention, and can be 3 mm to 4 mm, for example, 3.0 mm, 3.2 mm, 3.5 mm, 3.6 mm, 3.8 mm, 4.0 mm, etc.

[0165] The aqueous solution C can be obtained by mixing type I collagen with an aqueous solvent. It is understood that the aqueous solvent is a solvent suitable for microbial culture in the present invention. As a non-limiting example, the aqueous solvent can be water, a buffer solution for microbial culture, a microbial culture medium, etc. Reference can also be made to the Examples section below. It is understood that the pH environment is a condition suitable for the dissolution of type I collagen. The aqueous solution C may contain a pH regulator.

[0166] In some embodiments, the aqueous solution C contains type I collagen at a concentration of 1 mg / mL to 2 mg / mL, that is, in the aqueous solution C, the concentration of type I collagen can be 1 mg / mL to 2 mg / mL, for example, 1 mg / mL, 1.5 mg / mL, 2 mg / mL, etc.

[0167] In some embodiments, the type I collagen in the aqueous solution C is rat tail type I collagen.

[0168] In some embodiments, the volume ratio of the aqueous solution C to the mixture A is 1:(5-10); it can also be any of the following volume ratios or an interval consisting of any two of the following volume ratios: 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, etc.

[0169] In some embodiments, the aqueous solution C is laid on the surface of the first structural layer with a thickness of 0.4 mm to 0.8 mm, for example, 0.4 mm, 0.5 mm, 0.6 mm, 0.7 mm, 0.8 mm, etc.

[0170] In some embodiments, the thickness of the second structural layer can refer to the definition of the first aspect of the present invention, and can be 0.4 mm to 0.8 mm, for example, 0.4 mm, 0.5 mm, 0.6 mm, 0.7 mm, 0.8 mm, etc.

[0171] In some embodiments, the volume of the mixed solution M relative to the unit area of ​​the second structural layer is 1.5 μL / cm 2 ~3.2μL / cm 2 , which is equivalent to a volume of 1.5 μL to 3.2 μL per square centimeter of the mixed liquid M. The volume of the mixed liquid M relative to the unit area of ​​the second structural layer is, for example, 1.5 μL / cm 2 , 1.8μL / cm 2 , 2.0μL / cm 2, 2.5μL / cm 2 , 3.0μL / cm 2 , 3.2μL / cm 2 Etc., or can be an interval consisting of any two of the above-mentioned volume amounts per square centimeter.

[0172] In some embodiments, the culture container is a six-well plate, and the bottom area of ​​each culture well is about 9.6 square centimeters. The volume of the mixed solution M can be 15μL to 30μL, for example, 15μL, 20μL, 25μL, 30μL, etc., and can also be an interval consisting of any two of the above volumes. Taking the volume of the mixed solution M as 20μL as an example, the volume of the mixed solution M relative to the unit area of ​​the second structural layer is about 2.1μL / cm 2 .

[0173] In some embodiments, the volume of the mixed solution M may be 15 μL to 30 μL.

[0174] In some embodiments, the mixed solution M is relative to the unit culture area (cm 2 ) can have an average thickness of 15 μm to 32 μm, for example, about 15 μm, 20 μm, 20.8 μm, 25 μm, 30 μm, 32 μm, etc., or a range consisting of any two of the above thicknesses. For example, for a culture well of a six-well plate, the culture area of ​​each well is about 9.6 cm 2 When the volume of the mixed solution M is 20 μL, the average thickness per unit culture area is 20.8 μm.

[0175] In some embodiments, the second microbial culture medium can be selected from any one of TSB and LB, and can further be TSB medium.

[0176] In some embodiments, the mixed solution M is prepared by a method comprising the following steps: mixing the microbial suspension D with the culture medium M0 at 40 to 50° C.;

[0177] Further, the microbial suspension D contains the microorganisms and a microbial culture medium (referred to as the fourth microbial culture medium); the culture medium M0 contains agar and a microbial culture medium (referred to as the third microbial culture medium). The third microbial culture medium and the fourth microbial culture medium may be the same or different. When the third microbial culture medium and the fourth microbial culture medium are the same, the second microbial culture medium contains the microbial culture medium; when the third microbial culture medium and the fourth microbial culture medium are different, the second microbial culture medium contains a combination of the third microbial culture medium and the fourth microbial culture medium.

[0178] In some embodiments, the third microbial culture medium and the fourth microbial culture medium can be independently selected from any one of TSB and LB.

[0179] In some embodiments, the concentration of agar in the mixed solution M is 0.3% to 1.0% (w / v); for example, 0.3% (w / v), 0.4% (w / v), 0.45% (w / v), 0.5% (w / v), 0.6% (w / v), 0.8% (w / v), 0.9% (w / v), 1.0% (w / v), etc.

[0180] In some embodiments, the concentration of the microorganism in the mixed solution M is 10 5 ~10 7 CFU / mL.

[0181] In some embodiments, the number of microorganisms in the mixed solution M is 10 3 ~10 5 CFU.

[0182] In some embodiments, in the culture medium M0, the mass volume ratio of agar to the third microbial culture medium is 0.5% to 1.0% (w / v); for example, 0.5% (w / v), 0.6% (w / v), 0.7% (w / v), 0.8% (w / v), 0.9% (w / v), 1.0% (w / v), etc.

[0183] In some embodiments, the volume ratio of the microbial suspension D to the culture medium M0 is 0.02-0.05; for example, 0.02, 0.03, 0.04, 0.05, etc.

[0184] In some embodiments, the microbial suspension D is prepared by a method comprising the following steps: culturing the microorganisms in a fourth microbial culture medium at 37±1°C; wherein the culture time may be 18h to 24h; further, the fourth microbial culture medium may be selected from any one of TSB and LB.

[0185] In some embodiments, the microbial suspension D is prepared by a method comprising the following steps: at 37±1°C, inoculating at a density of 10 5 ~10 7 The microorganism with a concentration of CFU / mL is cultured in a fourth microbial culture medium for 18 hours to 24 hours; further, the fourth microbial culture medium can be selected from any one of TSB and LB.

[0186] In some embodiments, the microbial suspension D contains 0.5×10 9 ~5×10 9 CFU / mL of the described microorganism.

[0187] In some embodiments, the microbial suspension D contains about 10 9CFU / mL of the described microorganism.

[0188] In some embodiments, buffer B is replenished at least once every 24 hours; wherein, buffer B is a sodium chloride peptone buffer, and further, buffer B is a pH 7.0 sodium chloride peptone buffer. The height of the buffer B replenished each time can be 350 μm to 450 μm, for example, about 400 μm. Taking a six-well plate as an example, the volume of the buffer B replenished each time can be 300 to 450 μL (such as 400 μL); taking 400 μL of buffer B replenished each time as an example, it can be equivalent to forming an exudate with a height greater than 400 μm in the entire culture system (such as in the culture well). During the culture process, the model can also be constructed by simulating tissue exudate with a sodium chloride peptone buffer while preventing the biofilm from drying.

[0189] In the present invention, unless otherwise specified, "the height of buffer B replenished each time" corresponds to the average height of a certain volume of buffer B relative to the liquid paving area. It can be understood that this height can be sufficient to allow the entire biofilm layer to be immersed.

[0190] In step S300, the microorganisms are embedded in agar to simulate the microorganisms being embedded in the biofilm. The recovery rate confirms that the method can effectively recover the microorganisms embedded in the agar. It can be inferred that the method can also effectively recover the microorganisms embedded in the biofilm.

[0191] In some embodiments, the method for constructing the microbial biofilm model comprises the following steps S10, S20, S30 and S40:

[0192] S10: The microorganisms are inoculated into tryptic soy peptone liquid culture medium (such as TSB) respectively, and cultured at 37° C. for 18 to 24 hours to obtain a turbid bacterial suspension.

[0193] S20: Prepare mixture A of simulated wound composition materials, and compound the following ingredients together as a subcutaneous fat simulation layer, which includes: 10% (w / v) pig subcutaneous fat, 5% (v / v) sterile animal blood, 20% (v / v) animal serum (such as fetal bovine serum), 65% (v / v) TSB and 0.5% (w / v) agar. Add mixture A to a 6-well plate, add type I collagen aqueous solution after it solidifies, and wait for type I collagen to cross-link at room temperature to form a dermis simulation layer. A simulated wound is obtained.

[0194] In the present invention, "animal serum" and "animal-derived serum" have the same meaning and can be used interchangeably.

[0195] S30: Take 10 mL of TSB medium containing 0.5% (w / v) agar cooled to about 45° C. into a sterile centrifuge tube, add the bacterial suspension prepared in step S10, and vortex to mix.

[0196] S40: Take the bacterial suspension prepared in step S30, inoculate it onto the surface of the simulated wound prepared in step S20, culture it, and add a certain volume of buffer at regular intervals.

[0197] In step S20, animal-derived raw materials are used to replace the components of human wounds to culture microorganisms, and TSB culture medium commonly used for bacterial growth and agar are added as a physical support gel. A combination of pig subcutaneous fat, sterile animal blood, fetal bovine serum, TSB culture medium, agar and rat tail type I collagen can be selected.

[0198] In some embodiments, the buffer is a sodium chloride peptone buffer for simulation, and further can be 400 μL of pH 7.0 sodium chloride peptone buffer.

[0199] The present invention also provides a method for evaluating the maturity of a biofilm.

[0200] In some embodiments, the maturity of the biofilm layer is judged using a maturity evaluation method comprising the following steps (that is, the maturity evaluation method of the biofilm layer comprises the following steps):

[0201] Providing a microbial film layer to be tested and a microbial bacterial suspension; wherein the number of microorganisms in the microbial reference solution is similar to the number of microorganisms in the microbial film layer to be tested; unless otherwise specified, "the number of microorganisms in A and B is similar" means that the number of microorganisms in A and B is at the same order of magnitude or the difference between the number of microorganisms in A and B does not exceed 10% of the number of microorganisms in either A or B;

[0202] Provide antibiotic solution and sterile water, and simultaneously conduct the following four groups of experiments: Group 1: incubate the biofilm layer to be tested with the antibiotic solution; Group 2: incubate the biofilm layer to be tested with the sterile water; Group 3: incubate the microbial suspension with the antibiotic solution; Group 4: incubate the microbial suspension with the sterile water solution, wherein the four experimental groups are incubated under the same environment for the same time;

[0203] After the incubation, the number of microorganisms in the first, second, third and fourth groups of samples was tested and recorded as N z 、N p1 and N a and N p2 , calculate the parameter lg(N p1 )-lg(N z) and the parameter lg (N p2 )-lg(N a );

[0204] According to lg(N p2 )-lg(N a ) minus lg(N p1 )-lg(N z ) is used to obtain the resistance parameter Δlg of the microbial film layer to be tested. When Δlg is greater than or equal to a preset value, it is determined that the microbial film layer to be tested is mature.

[0205] In some embodiments, the preset value is 1, and when Δlg≥1, the microbial film layer to be tested is determined to be mature.

[0206] In some embodiments, when 1≤Δlg≤3, the microbial film layer to be detected is determined to be mature. In some embodiments, when 1<Δlg<3, the microbial film layer to be detected is determined to be mature.

[0207] The mechanism of the biological model maturity evaluation method is: once the biofilm is formed, theoretically, the resistance to antibiotics will increase (relative to the initial resistance or relative to the resistance of immature biofilms), that is, the decrease in the number of microorganisms after the action of antibiotics becomes smaller. The number of microorganisms is expressed in logarithmic form, and the decrease in the logarithmic value of the number of microorganisms in the experimental group is lg (N p1 )-lg(N z ) and the logarithmic decrease of the number of microorganisms in the control group lg(N p2 )-lg(N a ) is compared, and the difference Δlg=[lg(N p2 )-lg(N a )]-[lg(N p1 )-lg(N z )] By comparing with the preset indicators, we can draw a conclusion on whether the biofilm is mature.

[0208] When the microorganisms are different types of Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis and methicillin-resistant Staphylococcus aureus, the preset values ​​for judging whether the microorganism film layer is mature according to Δlg can all be 1.

[0209] The construction method provided by the present invention may include a method for evaluating the maturity of the biofilm layer. Further, from the perspective of biofilm drug resistance, a method is provided for determining whether microorganisms form mature biofilms.

[0210] In the present invention, the resistance of the biofilm to antibiotics is determined by testing the results of administering the same dose after a period of culture to reflect the resistance of the biofilm, thereby determining whether the biofilm is mature. The mature biofilm model determined in this way can provide assistance for biofilm treatment methods in the subsequent experimental stage.

[0211] In some embodiments, the antibiotic is any one of gentamicin, vancomycin or tobramycin.

[0212] Since different microorganisms have different resistances to different antibiotics, the method for evaluating biofilm maturity provided by the present invention is suitable for screening the maturity of biofilms of different microorganisms with multiple antibiotics.

[0213] Biofilm models with different culture days can be used to compare their resistance to antibiotics to verify the feasibility of the maturity evaluation method. According to the maturity evaluation method provided by the present invention, the resistance of the biofilm model to antibiotics is examined. The resistance of the biofilm model provided by the present invention to antibiotics can show corresponding changes with different culture days, which shows that the maturity evaluation method provided by the present invention can simulate the resistance changes of real wounds.

[0214] In some embodiments, the number of microorganisms in the microbial film layer to be detected is obtained by a method comprising the following steps:

[0215] In the presence of glass beads, the microbial film layer to be tested is vortexed and ultrasonically treated, and the number of microorganisms is measured by plate counting method after sampling from the suspension, and the number of microorganisms in the microbial film layer to be tested is calculated according to the measurement result of the plate counting method.

[0216] The construction method may include a method for counting microorganisms in a microbial film layer. Since some microorganisms are embedded in agar and some microorganisms grow into the solid matrix, once the biofilm is formed, it is hydrophobic and not easy to destroy. In order to accurately count, agar, collagen and biofilm are first dispersed by glass beads under high speed conditions, and then the microorganisms are further released by ultrasound. This method can improve the counting results of microorganisms and can accurately count the true value of microorganisms on the biofilm.

[0217] In some embodiments, the culture temperature is 37°C, with reasonable fluctuations allowed, such as 37±0.5°C, to simulate human body temperature, which has a constant temperature of 36.7°C.

[0218] In some embodiments, the culture time is 24 to 168 hours, for example, 24 h, 48 h, 72 h, 96 h, 120 h, 144 h, 168 h, etc.

[0219] In some embodiments, in the method for counting the number of microorganisms in the microbial film layer to be tested, the vortex treatment time is ≥5 min (further such as 5 to 15 min, such as 5 min, 10 min, 15 min, etc.), and the ultrasonic treatment time is ≥5 min (further such as 5 to 15 min, such as 5 min, 10 min, 15 min, etc.).

[0220] In some embodiments, the method for counting microorganisms in a biological model includes the following steps S410, S430 and S450:

[0221] S410: Mix a certain amount of microbial suspension with 0.5% (w / v) agarose in TSB medium and add to a 6-well plate. After solidification, recover it into a sterile centrifuge tube and rinse the wells with sodium chloride peptone buffer three times for a total of 10 mL. Transfer the rinse solution to a centrifuge tube, add 2 g of glass beads, and vortex at 2800 rpm at room temperature for 5 to 30 minutes.

[0222] S430: After vortexing, transfer the centrifuge tube to an ultrasonic cleaner and ultrasonicate at room temperature for 5 to 30 minutes.

[0223] S450: Dilute the bacterial suspension and count by the plate method. The count result is the number of viable microorganisms on the mature biofilm.

[0224] The microorganisms are fixed by inoculating them into agarose, and the microorganisms are fixed in the most difficult position to recover. If the microorganisms are recovered, the microorganisms on the surface biofilm are easier to recover. The microorganisms are embedded in agar to simulate the microorganisms being embedded in the biofilm. The recovery rate proves that this method can effectively recover the microorganisms embedded in agar, so it can be inferred that this method can also effectively recover the microorganisms embedded in the biofilm.

[0225] In the microbial counting method, it is necessary to control the appropriate vortex time and ultrasonic time to achieve technical accuracy.

[0226] In the method for constructing a microbial biofilm model provided by the present invention, animal-derived components are used to simulate the chronic wound layer of the skin to cultivate the microbial biofilm model; an accurate number of microorganisms can also be obtained through an improved counting method. In addition, the characteristics of microbial biofilm resistance to antibiotics are used to provide a method for judging the success of the biofilm model.

[0227] In some embodiments, the aforementioned method for evaluating biofilm maturity comprises the following steps S510, S520, S530, S540, S550, S560 and S570.

[0228] S510: The microorganisms are inoculated into a tryptic soy peptone liquid culture medium respectively and cultured at 37° C. A turbid bacterial suspension is obtained, which is concentrated by centrifugation to a bacterial suspension having a bacterial concentration similar to that of the biofilm.

[0229] S520: Mix an antibiotic solution of a certain concentration with the bacterial suspension prepared in S510 to obtain an antibiotic bacterial suspension, and allow the suspension to act for a period of time.

[0230] S530: dilute the bacterial suspension after the antibiotic action in S520 with a neutralizer buffer and count the plates.

[0231] S540: Add antibiotic solution with the same concentration as S520 to the surface of biofilm models cultured for different days and let it act for a period of time; the action time is the same as S520.

[0232] S550: Transfer the biofilm after the S540 antibiotic treatment to a sterile centrifuge tube and rinse the wells with neutralizer buffer three times for a total of 10 mL. Transfer the rinse solution to a centrifuge tube, add 2 g of glass beads, vortex at 2800 rpm at room temperature, dilute with neutralizer buffer, and count the plates.

[0233] S560: The same method as S540 and S550 was used, with sterile purified water replacing the antibiotic solution as a control. Other parameters were the same as S540 and S550.

[0234] S570: Calculate the decrease value of the logarithmic value of the number of microorganisms (the number of microorganisms can be measured using the lg value with 10 as the base), compare the resistance of the biofilm on the model and the microbial suspension to antibiotics, obtain the resistance parameter Δlg of the biofilm, compare Δlg with the preset index, and when Δlg is greater than or equal to the preset index (such as the preset value is 1), the biofilm is considered mature. Please refer to the calculation formula in the previous article.

[0235] In some embodiments, after inoculation of the mixed solution M, the mixed solution M is cultured for 1 day or more until a mature biofilm layer is formed.

[0236] In some embodiments, the microorganism is Pseudomonas aeruginosa (Pa), which can form a mature biofilm layer after one day of culture.

[0237] In some embodiments, the microorganism is Staphylococcus aureus (Sa), which can form a mature biofilm layer after 3 days of culture.

[0238] In a third aspect of the present invention, there is provided a use of a double-layer membrane in preparing a microbial biofilm model, wherein the double-layer membrane comprises a first structural layer and a second structural layer stacked in layers; the microbial biofilm model comprises microorganisms;

[0239] Wherein, the first structural layer, the second structural layer and the microorganism are as defined in the first aspect of the present invention.

[0240] The microbial biofilm model may include one of Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis and methicillin-resistant Staphylococcus aureus, and may further include any one of Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis and methicillin-resistant Staphylococcus aureus.

[0241] In a fourth aspect of the present invention, there is provided use of the microbial biofilm model described in the first aspect of the present invention or the microbial biofilm model obtained by the construction method described in the second aspect of the present invention in simulating chronic wounds in vitro.

[0242] In some embodiments, it is used in pilot phase dosing studies.

[0243] Some specific embodiments are provided below.

[0244] The embodiments of the present invention will be described in detail below in conjunction with examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples that do not specify specific conditions are preferably referred to the guidance provided in the present invention, and can also be based on the experimental manual or normal conditions in this area, can also be based on the conditions recommended by the manufacturer, or refer to experimental methods known in the art.

[0245] In the following specific embodiments, the measured parameters of raw material components may have slight deviations within the range of weighing accuracy unless otherwise specified. For temperature and time parameters, acceptable deviations caused by instrument test accuracy or operation accuracy are allowed.

[0246] In the following specific embodiments, the sources of raw materials involved, unless otherwise specified, can be obtained commercially.

[0247] Unless otherwise specified, "room temperature" is 20 to 30°C, and further 25°C.

[0248] TSB is trypticase soy peptone broth.

[0249] Example of biofilm model preparation

[0250] The microorganisms selected in the model preparation example are Staphylococcus aureus (Sa) and Pseudomonas aeruginosa (Pa), but other common pathogenic microorganisms (such as Staphylococcus epidermidis, methicillin-resistant Staphylococcus aureus, etc.) are also suitable for the model.

[0251] Preparation Examples 1 to 6 adopt substantially the same method, and the difference lies in the parameters shown in Table 1. The preparation method of the biological model is described in detail using the preparation example as an example.

[0252] Table 1. Summary of parameters for the preparation of microbial membrane models

[0253]

[0254] The method for preparing the biofilm model using Preparation Example 2 as an example is as follows.

[0255] The microorganisms were selected from the American Type Culture Collection (ATCC) and purchased.

[0256] Collagen was purchased from the market: Type I collagen (Solaibo Product No. C8062), the animal source is rat, and it can be cross-linked at room temperature. The collagen stock solution is a high-concentration acidic solution, and the pH is adjusted to about 7 by 0.1 mol / L sterile sodium hydroxide, and after dilution, the concentration of collagen in the solution is 1-2 mg / mL.

[0257] (1) The microorganisms were inoculated into TSB and cultured at 37°C for 18 to 24 hours to obtain a turbid bacterial suspension. After counting, the microbial concentration was about 10 9 CFU / mL.

[0258] (2) Preparation of simulated wound:

[0259] The following components were compounded to prepare a subcutaneous tissue simulation layer (first structural layer): animal-derived raw materials were 10% (w / v) subcutaneous fat of pigs, 5% (v / v) sterile defibrinated horse blood, 20% (v / v) fetal bovine serum and 65% (v / v) TSB; 0.5% (w / v) agar relative to the animal-derived raw materials. 3.3 mL of the mixture of the above components (referred to as mixture A) was taken into a 6-well plate, solidified to form a subcutaneous tissue simulation layer of about 3.5 mm thickness, and then 0.5 mL of collagen solution was added, and the mixture was allowed to stand at room temperature for 20 to 30 minutes, and the collagen was cross-linked to form a dermis simulation layer (second structural layer), thereby obtaining a simulated wound.

[0260] (3) Take 10 mL of TSB medium containing 0.5% (w / v) agar cooled to about 45° C. and put it into a sterile centrifuge tube, add 0.5 mL of the bacterial suspension obtained in step (1), vortex mix at 40-50° C., take 20 μL and inoculate it onto the simulated wound surface obtained in step (2), and culture it at 37° C. (the six-well plate is covered with a six-well plate lid to achieve air exchange), and replenish buffer B every 24 hours. Buffer B uses pH 7.0 sodium chloride peptone buffer, and the volume of each replenishment is 400 μL. Staphylococcus aureus is cultured for 3 days and Pseudomonas aeruginosa is cultured for 7 days until a biofilm is formed to simulate the formation of a biofilm on the wound surface.

[0261] (4) Add 480 μL of 1600 μg / mL gentamicin sulfate solution to the surface of the formed biofilm and incubate at 37°C for 24 hours.

[0262] (5) Transfer the biofilm to a sterile centrifuge tube and rinse the well where the model is located with neutralizer buffer three times, a total of 10 mL. Transfer the rinse solution to a centrifuge tube, add 2 g of glass beads, and vortex at 2800 rpm for 10 min at room temperature. After vortexing, transfer the centrifuge tube to an ultrasonic cleaner and sonicate at room temperature for 5 min. Dilute the bacterial suspension with the neutralizer, count the microorganisms by plate method, and record the microbial count result as N. m (m refers to Preparation Examples 1-6 in Table 1, and the results are recorded as N m1 、N m2 、N m3 、N m4 、N m5 、N m6 ), the positive group result was Np.

[0263] Table 2. Summary of results of preparation examples 1 to 6

[0264]

[0265] Table 2 "Positive group N p " is the test result of the number of microorganisms after the biofilm and sterile water were cultured in each preparation example. That is, the antibiotic solution in step (4) was replaced with sterile water.

[0266] In Table 2, the Δlg values ​​were obtained according to the test analysis described in the following "Method for evaluating whether the biofilm is mature". The Δlg values ​​after one day of cultivation can also be referred to Table 5.

[0267] Scientific notation: 1E+m represents 1×10 +m For example, 4.26E+09 means 4.26×10 +9 .

[0268] Test results analysis

[0269] According to N m The value analysis shows that the microorganisms can be massively multiplied in the biological models of Preparation Examples 1-3 and 5-6. However, the number of microorganisms in Preparation Example 4 decreased, which is presumably related to the high agar dosage of 1.5% (w / v) in the subcutaneous tissue simulation layer.

[0270] According to the analysis of the Δlg value obtained by the biofilm maturity evaluation method, the biofilms provided by Preparation Examples 2-6 can provide a certain antibiotic resistance effect, and the drug resistance is significantly increased. For Staphylococcus aureus, as the agar content in step (2) increases, such as increasing to 1.5% (w / v) in Preparation Example 1, the antibiotic resistance of the biofilm prepared thereby decreases. Therefore, under this condition, it is not easy for microorganisms to form biofilms.

[0271] In the above-mentioned Preparation Examples 1-3, after 3 days of culture, Staphylococcus aureus formed mature biofilms in Preparation Examples 2 and 3, but not in Preparation Example 1. After 7 days of culture, the biofilms of Pseudomonas aeruginosa in Preparation Examples 5 and 6 were mature, while the biofilm in Preparation Example 4 was not yet mature.

[0272] It should be noted that within the appropriate inoculation range, the initial microbial inoculation amount has little effect on the culture of mature biofilms. This is mainly because the microorganisms grow quickly. Under the condition of maintaining sufficient nutrients, the number of microorganisms can basically reach a certain value as the culture days increase.

[0273] Methods for counting microorganisms in biofilms

[0274] Counting method example 1.

[0275] Experimental group: Approximately 1 mL of 10 5 Add CFU microorganisms to 250mL of TSB medium containing 0.5% agar at about 45°C, mix well, and add to a 6-well plate, 3.8mL per well. Wait for 10 to 30 minutes for it to solidify, transfer to a sterile centrifuge tube, and rinse the well where the model is located with sodium chloride peptone buffer three times, a total of 10mL. Transfer the rinse solution to a centrifuge tube, add 2g of glass beads, and vortex at 2800rpm at room temperature for 10 minutes. After vortexing, transfer the centrifuge tube to an ultrasonic cleaner and sonicate at room temperature for 5 minutes. Take 1mL for plate counting.

[0276] Positive control group: Take about 1 mL of 10 5 The CFU of microorganisms was added to 250 mL of pH 7.0 sodium chloride peptone buffer, mixed, and then 3.8 mL of the mixture was taken into a sterile test tube, 10 mL of pH 7.0 sodium chloride peptone buffer was added, and 1 mL was taken for counting after mixing.

[0277] The recovery rate is = the counting result of the experimental group / the counting result of the positive control group.

[0278] Example 2: The vortex time in the experimental group of counting method example 1 was changed to 5 minutes, and the remaining steps were the same as those of counting method example 1.

[0279] Example 3. The vortex time in the experimental group of counting method example 1 was changed to 15 minutes, and the remaining steps were the same as those of counting method example 1.

[0280] Example 4. The vortex time in the experimental group of counting method example 1 was changed to 5 minutes, the room temperature ultrasonic time was changed to 10 minutes, and the remaining steps were the same as those of counting method example 1.

[0281] Example 5. The vortex time in the experimental group of counting method example 1 was changed to 10 minutes, the room temperature ultrasonic time was changed to 10 minutes, and the remaining steps were the same as those in counting method example 1.

[0282] Example 6. The vortex time in the experimental group of counting method example 1 was changed to 15 minutes, the room temperature ultrasonic time was changed to 10 minutes, and the remaining steps were the same as those of counting method example 1.

[0283] Example 7. The vortex time in the experimental group of Counting Method Example 1 was changed to 5 minutes, the room temperature ultrasonic time was changed to 15 minutes, and the remaining steps were the same as Counting Method Example 1.

[0284] Example 8. The vortex time in the experimental group of Counting Method Example 1 was changed to 10 minutes, the room temperature ultrasonic time was changed to 15 minutes, and the remaining steps were the same as Counting Method Example 1.

[0285] Example 9. The vortex time in the experimental group of Counting Method Example 1 was changed to 15 minutes, the room temperature ultrasonic time was changed to 15 minutes, and the remaining steps were the same as Counting Method Example 1.

[0286] Example 10, the vortex time in the experimental group of counting method example 1 was changed to 2 minutes, the room temperature ultrasonic time was changed to 5 minutes, and the remaining steps were the same as those of counting method example 1.

[0287] Table 3. Summary of counting results of counting method examples 1 to 10

[0288]

[0289] Table 3 lists the recovery of microorganisms in agar under different action conditions for two different microorganisms (Sa and Pa). When the recovery rate is greater than 70%, the counting accuracy requirement is met.

[0290] Among the ten treatment methods of Examples 1 to 10, the recovery rates of microorganisms in Examples 1 to 9 were all greater than 80%, while the recovery rate in Example 10 was less than 50%. It can be seen that the purpose of recovering microorganisms can only be achieved when both the ultrasonic time and the vortex time are greater than 5 minutes.

[0291] Methods for evaluating biofilm maturity

[0292] In this example, unless otherwise specified, the base of the logarithm of the number of microorganisms is 10 and is expressed as lg.

[0293] The biofilms cultured for 1 day were prepared by the methods of Preparation Examples 2 and 5 in Table 1 above.

[0294] S301. Biofilm group: The microorganisms were inoculated in TSB and cultured at 37°C for 24 hours (i.e., one day). The turbid bacterial suspension was centrifuged at 5000 rpm for 15 minutes to concentrate it to a bacterial suspension with a similar bacterial concentration to that of the biofilm, and the count was recorded as N. a .

[0295] S302. Mix 6400 μg / mL gentamicin sulfate solution with the bacterial suspension in S301 at a ratio of 1:3 and allow to react at 37°C for 24 hours. Dilute the bacterial suspension with a neutralizer and count by plate counting. The count result is recorded as N. a .

[0296] S303. Bacterial suspension action group: 480 μL (thickness about 0.5 mm) of 1600 μg / mL gentamicin sulfate solution was added to the surface of the biofilm model cultured for 1 day and allowed to act at 37°C for 24 hours.

[0297] S304. Transfer the biofilm model (S303) after the action to a sterile centrifuge tube, and rinse the well where the model is located with the neutralizer buffer three times, a total of 10 mL. The rinse solution is transferred to the centrifuge tube, 2g of glass beads are added, and vortexed at 2800rpm for 10 minutes at room temperature. After vortexing, transfer the centrifuge tube to an ultrasonic cleaner and ultrasonicate at room temperature for 5 minutes. The neutralizer dilutes the bacterial suspension, and the plate method is used to count the count result, and the count result is recorded as N z .

[0298] S305. Use the same method as S303 and S304, replace the gentamicin sulfate solution with sterile purified water as the positive control, and record the count result as N pa (Bacterial suspension positive group, corresponding to the aforementioned N p2 ) and N pz (Biofilm positive group, corresponding to the aforementioned N p1 ).

[0299] S306. The bactericidal parameter of antibiotics on the biofilm model is lg(N pz )-lg(N z ); The bactericidal parameter of antibiotics on bacterial suspension is lg(N pa )-lg(N a ).

[0300] Table 4. The effects of gentamicin on the biofilm model and microbial suspension cultured for 1 day.

[0301]

[0302] Table 5. Analysis of the reduction in the logarithmic value of the number of microorganisms killed by gentamicin in the biofilm model and microbial suspension cultured for 1 day

[0303]

[0304] According to the results in Tables 4 and 5, under the action of the same antibiotic gentamicin, the logarithmic value of the number of microorganisms in the biofilm model of Sa and Pa was lower than that in the suspension method. When Δlg is greater than or equal to 1, the biofilm can be considered mature. Therefore, it can be considered that the Pa group formed a mature biofilm after one day of culture, and the Sa group was not mature after one day of culture. The culture time needs to be extended. After further culture for 3 days, the Δlg value in this case is 1.11, and the biofilm is mature (see also Table 6).

[0305] Application of biofilm maturity evaluation method

[0306] Two groups of biofilms were prepared using the methods of Preparation Example 2 and Preparation Example 5 in Table 1 above, one group using Staphylococcus aureus and the other using Pseudomonas aeruginosa. At least 6 biofilms were prepared in each group for parallel experiments.

[0307] S401. For Staphylococcus aureus, 480 μL (thickness about 0.5 mm) of 1600 μg / mL gentamicin solution was added to the surface of the biofilm model after culturing for 1 day and 3 days, respectively, and the mixture was allowed to react at 37°C for 24 hours. For Pseudomonas aeruginosa, 480 μL (thickness about 0.5 mm) of 1600 μg / mL gentamicin sulfate solution was added to the surface of the biofilm model after culturing for 1 day, 3 days, 5 days and 7 days, respectively, and the mixture was allowed to react at 37°C for 24 hours.

[0308] S402. Transfer the biofilm after the action to a sterile centrifuge tube, and rinse the well where the model is located with the neutralizer buffer three times, a total of 10 mL. The rinse solution is transferred to the centrifuge tube, 2g of glass beads are added, and vortexed at 2800rpm for 10 minutes at room temperature. After vortexing, transfer the centrifuge tube to an ultrasonic cleaner and ultrasonicate at room temperature for 5 minutes. Dilute the bacterial suspension with the neutralizer, count by the plate method, and record the result of the gentamicin group as N n , n is the number of days of biofilm model culture.

[0309] S403. In the same way, sterile purified water was used instead of the antibiotic solution as a positive control, and the counting result was recorded as N p .

[0310] S404. The bactericidal parameter of antibiotics on the biofilm model is lg(N p )-lg(N n ).

[0311] Table 6. Resistance of biofilm models to gentamicin at different culture days

[0312]

[0313] According to the test results (see Table 6), the resistance of biofilm to gentamicin is different in different culture time periods, indicating that this method can provide a theoretical basis for judging whether biofilm is formed and its maturity.

[0314] The technical features of the above-mentioned embodiments and examples can be combined in any appropriate manner. In order to make the description concise, not all possible combinations of the technical features in the above-mentioned embodiments and examples are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0315] The above embodiments only express several implementation methods of the present invention, which is convenient for understanding the technical solution of the present invention in detail, but it cannot be understood as limiting the scope of protection of the present invention. It should be pointed out that for ordinary technicians in this field, without departing from the concept of the present invention, several variations and improvements can be made, which all belong to the protection scope of the present invention. In addition, it should be understood that after reading the above teaching content of the present invention, those skilled in the art can make various changes or modifications to the present invention, and the equivalent forms obtained also fall within the protection scope of the present invention. It should also be understood that the technical solutions obtained by those skilled in the art on the basis of the technical solution provided by the present invention through logical analysis, reasoning or limited experiments are all within the protection scope of the claims attached to the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the content of the attached claims, and the description and drawings can be used to explain the content of the claims.

Claims

1. A microbial biofilm model, characterized in that: It includes a first structural layer, a second structural layer and a biofilm layer stacked in sequence; Wherein, the first structural layer comprises animal-derived raw materials and agar; the animal-derived raw materials comprise the following components: 5% to 15% (w / v) of animal subcutaneous fat, 2% to 6% (v / v) of sterile animal blood, 10% to 25% (v / v) of sterile animal serum and 55% to 80% (v / v) of a first microbial culture medium; in the first structural layer, the weight volume percentage of agar relative to the animal-derived raw materials is 0.3% to 0.8% (w / v); The second structural layer is a hydrogel containing 1 mg / mL to 2 mg / mL type I collagen; The biofilm layer comprises 10 3 ~10 5 The invention discloses a microorganism containing CFU and a second microorganism culture medium containing 0.3% to 0.8% (w / v) agar, wherein the microorganism comprises one of Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis and methicillin-resistant Staphylococcus aureus.

2. The microbial biofilm model according to claim 1, characterized in that Satisfy one or more of the following characteristics: The animal-derived raw material is selected from one or more of pigs, cattle, sheep, horses, rabbits and mice; The sterile animal blood is sterile defibrinated animal blood; The first microbial culture medium is selected from any one of TSB and LB; The matrix component in the second structural layer is cross-linked type I collagen; The thickness of the first structural layer is 3 mm to 4 mm; The thickness of the second structural layer is 0.4 mm to 0.8 mm; The second microbial culture medium is any one of TSB and LB.

3. The microbial biofilm model according to claim 1 or 2, characterized in that: Meet one or more of the following characteristics: Feature a1: The animal-derived raw material comprises the following components: 5% to 15% (w / v) of animal subcutaneous fat, 2% to 6% (v / v) of sterile defibrinated animal blood, 15% to 25% (v / v) of sterile animal serum and 55% to 80% (v / v) of the first microbial culture medium; and Feature b1: In the first structural layer, the weight volume percentage of agar relative to the animal-derived raw material is 0.3% to 0.5% (w / v).

4. A method for constructing a microbial biofilm model, characterized in that: The steps include: The animal-derived raw material and agar are mixed to obtain a mixture A, which is solidified to form a first structural layer; wherein the animal-derived raw material comprises the following components: 5% to 15% (w / v) of animal subcutaneous fat, 2% to 6% (v / v) of sterile animal blood, 10% to 25% (v / v) of sterile animal serum and 55% to 80% (v / v) of a first microbial culture medium; in the first structural layer, the weight volume percentage of agar relative to the animal-derived raw material is 0.3% to 0.8% (w / v); Covering at least a portion of the surface of the first structural layer with an aqueous solution C containing type I collagen, and forming a second structural layer through cross-linking; wherein the concentration of type I collagen in the aqueous solution C is 1 mg / mL to 2 mg / mL; A mixed solution M containing microorganisms, a second microorganism culture medium and agar is inoculated onto at least a portion of the surface of the second structural layer and cultured until a biofilm layer is formed. The biofilm layer comprises 10 3 ~10 5 CFU of microorganisms; wherein the microorganism includes one of Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis and methicillin-resistant Staphylococcus.

5. The construction method according to claim 4, characterized in that: The maturity of the biofilm layer is judged by a maturity evaluation method comprising the following steps: Providing a microbial film layer to be tested and a microbial bacterial suspension; wherein the number of microorganisms in the microbial bacterial suspension is similar to the number of microorganisms in the microbial film layer to be tested; Provide antibiotic solution and sterile water, and simultaneously conduct the following four groups of experiments: Group 1: incubate the biofilm layer to be tested with the antibiotic solution; Group 2: incubate the biofilm layer to be tested with the sterile water; Group 3: incubate the microbial suspension with the antibiotic solution; Group 4: incubate the microbial suspension with the sterile aqueous solution; wherein the four experimental groups are incubated for the same time under the same environment; the antibiotics include at least one of gentamicin, vancomycin and tobramycin; After the incubation, the number of microorganisms in the first, second, third and fourth groups of samples was tested and recorded as N z 、N p1 and N a and N p2 , calculate the parameter lg(N p1 )-lg(N z ) and the parameter lg (N p2 )-lg(N a ); According to lg(N p2 )-lg(N a ) minus lg(N p1 )-lg(N z ) is used to obtain the resistance parameter Δlg of the microbial film layer to be tested. When Δlg≥1, it is determined that the microbial film layer to be tested is mature.

6. The construction method according to claim 5, characterized in that: The number of microorganisms in the microbial film layer to be tested is obtained by a method comprising the following steps: In the presence of glass beads, the microbial film layer to be tested is vortexed and ultrasonically treated, and the number of microorganisms is measured by plate counting method after sampling from the suspension, and the number of microorganisms in the microbial film layer to be tested is calculated according to the measurement result of the plate counting method.

7. The construction method according to claims 4 to 6, characterized in that: The step of culturing until a biofilm layer is formed satisfies one or more of the following characteristics: The culture temperature was 37°C; The culture time is 24 to 168 hours; Buffer B is replenished at least once every 24 hours; wherein the buffer B is a pH 7.0 sodium chloride peptone buffer; and the height of the buffer B replenished each time is 350 μm to 450 μm.

8. The construction method according to any one of claims 4 to 6, characterized in that: Satisfy one or more of the following characteristics: The animal-derived raw material is selected from one of pigs, cattle, sheep, horses, rabbits and mice; The first microbial culture medium is selected from any one of TSB and LB; The second microbial culture medium is any one of TSB and LB; The laying thickness of the mixture A is 3 mm to 4 mm; The thickness of the first structural layer is 3 mm to 4 mm; The aqueous solution C contains type I collagen at a concentration of 1 mg / mL to 2 mg / mL; The volume ratio of the aqueous solution C to the mixture A is 1:(5-10); The thickness of the aqueous solution C on the surface of the first structural layer is 0.4 mm to 0.8 mm; The volume of the mixed solution M per unit area of ​​the second structural layer is 1.5 μL / cm 2 ~3.2μL / cm 2 .

9. The construction method according to any one of claims 4 to 6, characterized in that: The mixed solution M is prepared by a method comprising the following steps: mixing the microbial suspension D with the culture medium M0 at 40-50°C; Wherein, the microbial suspension D contains the microorganisms and a fourth microbial culture medium; and the culture medium M0 contains agar and a third microbial culture medium.

10. The construction method according to claim 9, characterized in that: Satisfy one or more of the following characteristics: In the mixed solution M, the concentration of agar is 0.3% to 1.0% (w / v); In the mixed solution M, the concentration of the microorganism is 10 5 ~10 7 CFU / mL; In the mixed solution M, the number of microorganisms is 10 3 ~10 5 CFU; In the culture medium M0, the mass volume ratio of agar to the third microbial culture medium is 0.5% to 1.0% (w / v); The volume ratio of the microbial suspension D to the culture medium M0 is 0.02 to 0.05; The microbial suspension D is prepared by a method comprising the following steps: culturing the microorganism in the fourth microbial culture medium at 37±1° C. for 18 h to 24 h; The fourth microbial culture medium is selected from any one of TSB and LB; The microbial suspension D contained 0.5×10 9 ~5×10 9 CFU / mL of the microorganism; The third microbial culture medium is selected from any one of TSB or LB.

11. The construction method according to any one of claims 4 to 6, characterized in that: Meet one or more of the following characteristics: Feature a2: The animal-derived raw material comprises the following components: 5% to 15% (w / v) of animal subcutaneous fat, 2% to 6% (v / v) of sterile defibrinated animal blood, 15% to 25% (v / v) of sterile animal serum and 55% to 80% (v / v) of a second microbial culture medium; and Feature b2: In the first structural layer, the weight volume percentage of agar relative to the animal-derived raw material is 0.3% to 0.5% (w / v).

12. Use of a double-layer membrane in preparing a microbial biofilm model, characterized in that: The double-layer membrane comprises a first structural layer and a second structural layer which are stacked; the microbial biofilm model comprises one of Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus epidermidis and methicillin-resistant Staphylococcus aureus; Wherein, the first structural layer and the second structural layer are as defined in any one of claims 1 to 3.

13. Use of the microbial biofilm model according to any one of claims 1 to 3 or the microbial biofilm model obtained by the construction method according to any one of claims 4 to 11 in simulating chronic wounds in vitro.